Xvivo Perfusion AB (publ)
Xvivo Perfusion AB (publ) Fundamental Analysis
Xvivo Perfusion AB (publ) (XVIPY) shows moderate financial fundamentals with a PE ratio of 66.73, profit margin of 13.53%, and ROE of 5.29%. The company generates $0.8B in annual revenue with strong year-over-year growth of 37.63%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 64.9/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze XVIPY's fundamental strength across five key dimensions:
Efficiency Score
WeakXVIPY struggles to generate sufficient returns from assets.
Valuation Score
ModerateXVIPY shows balanced valuation metrics.
Growth Score
ExcellentXVIPY delivers strong and consistent growth momentum.
Financial Health Score
ExcellentXVIPY maintains a strong and stable balance sheet.
Profitability Score
WeakXVIPY struggles to sustain strong margins.
Key Financial Metrics
Is XVIPY Expensive or Cheap?
P/E Ratio
XVIPY trades at 66.73 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, XVIPY's PEG of -0.40 indicates potential undervaluation.
Price to Book
The market values Xvivo Perfusion AB (publ) at 3.55 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 74.63 times EBITDA. This signals the market has high growth expectations.
How Well Does XVIPY Make Money?
Net Profit Margin
For every $100 in sales, Xvivo Perfusion AB (publ) keeps $13.53 as profit after all expenses.
Operating Margin
Core operations generate 8.46 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $5.29 in profit for every $100 of shareholder equity.
ROA
Xvivo Perfusion AB (publ) generates $4.67 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Xvivo Perfusion AB (publ) generates limited operating cash flow of $78.51M, signaling weaker underlying cash strength.
Free Cash Flow
Xvivo Perfusion AB (publ) generates weak or negative free cash flow of $1.98M, restricting financial flexibility.
FCF Per Share
Each share generates $0.02 in free cash annually.
FCF Yield
XVIPY converts 0.03% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
66.73
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.40
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.55
vs 25 benchmark
P/S Ratio
Price to sales ratio
9.03
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.05
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.81
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.05
vs 25 benchmark
ROA
Return on assets percentage
0.05
vs 25 benchmark
ROCE
Return on capital employed
0.03
vs 25 benchmark
How XVIPY Stacks Against Its Sector Peers
| Metric | XVIPY Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 66.73 | 29.45 | Worse (Expensive) |
| ROE | 5.29% | 779.00% | Weak |
| Net Margin | 13.53% | -24936.00% (disorted) | Strong |
| Debt/Equity | 0.05 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 4.81 | 4.65 | Strong Liquidity |
| ROA | 4.67% | -19344.00% (disorted) | Weak |
XVIPY outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Xvivo Perfusion AB (publ)'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
213.52%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
2834.91%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
217.55%
Industry Style: Defensive, Growth, Innovation
High Growth